Abstract: Dressings, systems, and methods are disclosed that, in some embodiments, relate to treating a tissue site. In one embodiment, a dressing may include a manifold, a retention pouch, a sealing member, and a conduit interface. The manifold may be adapted to distribute reduced pressure to the tissue site, and the retention pouch may be adapted to retain and manage fluid extracted from the tissue site. The sealing member may cover the retention pouch and the manifold to provide a sealed space with the tissue site. The conduit interface may be in fluid communication with the sealed space and an exterior surface of the sealing member. The dressing may be utilized with a therapy device operable to control reduced pressure in the dressing and fluid flow over the sealing member.

Abstract: A reduced-pressure system for delivering reduced pressure for medical purposes to a desired site and to receive fluids in one instance includes a reservoir having an interior space operable to contain the fluids. A reduced-pressure delivery conduit is placed in fluid communication with the interior space for delivering the reduced pressure to the desired site. A source conduit and a pressure sensor conduit are placed in fluid communication with the interior space. A pressure sensor is placed in fluid communication with the pressure sensor conduit. A reduced-pressure source is placed in fluid communication with the source conduit. A reduced-pressure control unit is associated with the pressure sensor and the reduced-pressure source and is operable to receive pressure data from the pressure sensor and supply data from the reduced-pressure source and to determine when a reservoir-full/blockage condition exists. Other systems and methods are presented.

Abstract: A system, apparatus, and method for treating a tissue site with reduced pressure includes a connector having a connector body. The connector body includes a cavity and a cavity aperture. The connector also includes a conduit port fluidly coupling a conduit to the cavity. The connector further includes a base adjacent the cavity aperture that is configured to be positioned adjacent a drape. The cavity is configured to be fluidly coupled to a manifold through an aperture of the drape. The connector also includes a sensing probe having a proximal end configured to be fluidly coupled to the conduit and a distal end extending to the cavity aperture. The distal end is configured to be positioned adjacent to and in fluid communication with a manifold.

Abstract: In one example embodiment, a dressing connector is described that provides a first fluid path between a first connector and a second connector, and a second fluid path between a third connector and a fourth connector. A liquid barrier may be disposed in the first fluid path. The first fluid path and the second fluid path are generally exposed to an exterior surface of the dressing connector. In some embodiments, a tube may also be bonded to the third connector to provide a third fluid path between the dressing connector and another component. In more particular embodiments, the liquid barrier may be a filter, such as a hydrophobic bacterial filter, a sintered polymer filter, and/or a charcoal filter.

Abstract: A reduced-pressure system for delivering reduced pressure for medical purposes to a desired site and to receive fluids in one instance includes a reservoir having an interior space operable to contain the fluids. A reduced-pressure delivery conduit is placed in fluid communication with the interior space for delivering the reduced pressure to the desired site. A source conduit and a pressure sensor conduit are placed in fluid communication with the interior space. A pressure sensor is placed in fluid communication with the pressure sensor conduit. A reduced-pressure source is placed in fluid communication with the source conduit. A reduced-pressure control unit is associated with the pressure sensor and the reduced-pressure source and is operable to receive pressure data from the pressure sensor and supply data from the reduced-pressure source and to determine when a reservoir-full/blockage condition exists. Other systems and methods are presented.

Abstract: TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

Abstract: Fluid supply systems and methods for therapeutic fluid delivery systems, including those used for negative pressure wound therapy (NPWT) systems and methods.

Abstract: Provided are systems and methods for delivery of fluid to a wound therapy dressing. In exemplary embodiments, a pressure source provides negative pressure to a wound dressing and a biasing mechanism provides positive pressure to a fluid reservoir.

Abstract: Systems and methods for treating a plurality of tissue sites include a multi-port therapy unit. The multi-port therapy unit includes a plurality of patient-side ports each fluidly coupled to a plurality of conduits and a fluid reservoir fluidly coupled to the plurality of ports. A plurality of pressure sensors are associated with the plurality of patient-side ports to determining a pressure associated with each conduit. A controller is operatively coupled to the plurality of pressure sensors to receive treatment pressure data, monitor pressure for each pressure sensor of the plurality of pressure sensors, and signal an alarm condition if the pressure is outside of a pre-selected range. The system includes a reduced-pressure source fluidly coupled to a dressing at each tissue site through the multi-port therapy unit.

Abstract: Fluid supply systems and methods for therapeutic fluid delivery systems, including those used for negative pressure wound therapy (NPWT) systems and methods.

Abstract: Inline storage pouches and systems for receiving and retaining body fluids from an animal are presented. The inline storage pouch include a flexible pouch body has an interior portion with a fluid storage material disposed within the interior portion. In addition to receiving body fluids, the inline storage pouch may fluidly couple a pressure sensing conduit between a first port and a second port using a first bypass conduit. The first port may be a patient-port interface. The second port may be a device-port interface. Multiple sensors and bypass conduits may be included and associated with a microprocessor that is configured to locate blockages or determine when the inline storage pouch is full. Another inline storage pouch has two chambers and receives and discharges fluids from a pouch connector. Other pouches, systems, and methods are presented herein.

Abstract: A reduced pressure apparatus includes a first casing portion and a second casing portion slidably coupled to the first casing portion such that the first casing portion is compressible into a plurality of positions relative to the second casing portion. The plurality of positions includes a fully compressed position and a fully uncompressed position. An indicator is disposed on at least one of the first casing portion and the second casing portion, the indicator being exposed when the first casing portion is in the fully uncompressed position.

Abstract: A reduced pressure apparatus includes a first casing portion and a second casing portion slidably coupled to the first casing portion such that the first casing portion is compressible into a plurality of positions relative to the second casing portion. The plurality of positions includes a fully compressed position and a fully uncompressed position. An indicator is disposed on at least one of the first casing portion and the second casing portion, the indicator being exposed when the first casing portion is in the fully uncompressed position.

Abstract: The present invention comprises TGR5 agonists of structural formula I, wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which TGR5 is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which TGR5 is a mediator or is implicated.

Abstract: A highly active synthetic epothilone compound whose activity exceeds that of either epothilone EpoA or EpoB when assayed as a cytotoxic agent against a cancer cell line is disclosed as is a pharmaceutical composition containing the synthetic epothilone.

Abstract: A highly active synthetic epothilone compound whose activity exceeds that of either epothilone EpoA or EpoB when assayed as a cytotoxic agent against a cancer cell line is disclosed as is a pharmaceutical composition containing the synthetic epothilone.

Abstract: Fluid supply systems and methods for therapeutic fluid delivery systems, including those used for negative pressure wound therapy (NPWT) systems and methods.